US EditionPublished • loading... • Updated
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
ANVISA approved MINJUVI with rituximab and lenalidomide for relapsed follicular lymphoma, based on Phase 3 data showing 57% lower risk of progression, Knight Therapeutics said.
Summary by WBOC 16
8 Articles
8 Articles
Cambridge Times+4 Reposted by 4 other sources
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have…
·Cambridge, Canada
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left5Leaning Right1Center2Last UpdatedBias Distribution63% Left
Bias Distribution
- 63% of the sources lean Left
63% Left
L 63%
C 25%
12%
Factuality
To view factuality data please Upgrade to Premium
